Number needed to harm: Its limitations in psychotropic drug safety research

Journal of Nervous and Mental Disease

Volumn 201, Issue 8, 2013, Pages 714-718

  Safer, Daniel J ^a   Zito, Julie M ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Adverse drug events; Clinical trials; Likelihood to help or harm (LHH); Number needed to harm (NNH); Number needed to treat (NNT)

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLONIDINE; FENFLURAMINE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PEMOLINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SIBUTRAMINE; TRAZODONE;

CASE CONTROL STUDY; COMPARATIVE STUDY; DIZZINESS; DRUG SAFETY; GROUP THERAPY; HEADACHE; HUMAN; INCREASED APPETITE; LIVER FAILURE; MAJOR DEPRESSION; MEDLINE; METABOLIC SYNDROME X; NAUSEA; OBESITY; POSTMARKETING SURVEILLANCE; REVIEW; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; PSYCHOTROPIC DRUGS; RESEARCH DESIGN;

EID: 84881342975     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0b013e31829c5013     Document Type: Review

References (58)

1. Akobeng AK (2005) Understanding measures of treatment effect in clinical trials. Arch Dis Child. 90: 54-56. (Pubitemid 40052254)
2. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, Chandra M, Reed G, Gurwitz JH (2011) Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 128: 1135-1141.
3. Avorn J (2012) Two centuries of assessing drug risks. N Engl J Med. 367: 193-197.
4. Berry DC, Knapp P, Raynor T (2006) Expressing medicine side effects: Assessing the effectiveness of absolute risk, relative risk, and number needed to harm, and the provision of baseline information. Patient Educ Couns. 63: 89-96. (Pubitemid 44348864)
5. Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, Muniz R (2012) A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended release in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 32: 637-644.
6. Brent DA (2009) Selective serotonin reuptake inhibitors and suicidality: A guide to the perplexed. Can J Psychiatry. 54: 72-74.
7. Bridge JA, Iyengar S, Salary CB, Barbe B, Birmaher B, Pincus HA, Ren L, Brent DA (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA. 297: 1683-1696.
8. Brooks JQ, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME (2011) Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry. 72: 240-247.
9. Citrome L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety. J Clin Psychiatry. 68: 1876-1885.
10. Citrome L (2010) Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm and likelihood to be helped or harmed. Postgrad Med. 122: 39-48.
11. Citrome L, Weiss-Citrome A (2012) A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and the likelihood to be helped or harmed? Postgrad Med. 124: 83-93.
12. Correll CU, Kratochvil CJ, March JS (2011) Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 72: 655-670.
13. Derry S, Moore RA (2007) Atypical antipsychotics in bipolar disorder: Systematic review of randomized trials. BMC Psychiatry. 7:40. doi:10.1186/1471-244X- 7-40. (Pubitemid 47593124)
14. Duffy FF, Narrow WE, Rae DS, West JC, Zarin DA, Rubio-Stipec M, Pincus HA, Regier DA (2005) Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol. 15: 12-25. (Pubitemid 40365910)
15. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S (2000) Olanzapine for schizophrenia. Cochrane Database Syst Rev. CD001359.
16. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (2005) Olanzapine for schizophrenia. Cochrane Database Syst Rev. CD001359.
17. Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNutty S, Weller E, Waslick B (2006) Treatment for adolescents with depression study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 46: 1440-1455. (Pubitemid 44900917)
18. Engels JM, Diehr P (2003) Imputation of missing longitudinal data: A comparison of methods. J Clin Epidemiol. 56: 968-976. (Pubitemid 37268084)
19. FDA Safety Alert (2010) Meridia (subutramine): market withdrawal due to risk of serious cardiovascular events. Retrieved from http: www.fda.gov/safety/ medwatch/ safetyinformation/safetyalertsforhuman medicalproducts/ucm228830.htm. Accessed December 2012.
20. Friedman ES, Wisniewski SR, Gilmer W, Nierenberg AA, Rush A, Fava M, Zisook W, Balasubramani GK, Trivedi MH (2009) Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: Results of the NIMH STAR (*)D trial. Depress Anxiety. 26: 612-621.
21. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR (2011) Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 72: 1063-1071.
22. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A (2000) Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. CD002306.
23. Gopal S, Berwaerts J, Nuamah I, Akhas K, Coppula D, Daily E, Hough D, Palumbo J (2011) Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatric Dis Treat. 7: 93-101.
24. Gopal S, Berwaerts J, Nuamah I, Akhas K, Coppula D, Daily E, Hough DW, Palumbo JM (2010) Efficacy and safety of long-acting injectable paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for long-term treatment in patients with schizophrenia using number needed to treat and number needed to harm. Biol Psychiatry. 67:76S-77S.
25. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 63: 332-339. (Pubitemid 43345358)
26. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head to head comparison studies of second-generation antipsychotics. Am J Psychiatry. 163: 185-194. (Pubitemid 44480836)
27. Hutton JL (2010) Misleading statistics: The problems surrounding number needed to treat and number needed to harm. Pharm Med. 24: 145-149.
28. Hutton P, Morrrison AP, Yung AR, Taylor PJ, French P, Dunn G (2012) Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand. 120: 1-11.
29. Institute of Medicine (2012) Ethical and scientific issues in studying the safety of approved drugs. Washington, DC: The National Academies Press.
30. Ioannidis JP, Evans SJ, Gotzshe PC, O'Neill RT, Altman DG, Schulz K, Moher D (2004) Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med. 141: 781-788. (Pubitemid 39524916)
31. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA (1995) Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 52: 756-765.
32. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M (2009) Discontinuation due to randomized trials of orlistat, sibutramine and rimonabant: A meta-analysis. Obes Rev. 10: 564-575.
33. Kaufman DW, Shapiro S (2000) Epidemiological assessment of drug-induced disease. Lancet. 356: 1339-1343.
34. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW (2005) Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs. Arch Gen Psychiatry. 62: 1305-1312. (Pubitemid 41746608)
35. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012) Exploratory analysis of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry. 73: 856-864.
36. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. CD006918.
37. Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 318: 1728-1733.
38. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K (2006) Attrition in randomized controlled clinical trials: Methodological issues in psychopharmacology. Biol Psychiatry. 59: 1001-1005. (Pubitemid 43870057)
39. March JS, Klee RJ, Kremer CM (2006) Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Psychopharmacol. 16: 91-102.
40. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A (1997) Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 23: 176-194. (Pubitemid 27514710)
41. Moreno C, Arango C, Parelland M, Shaffer D, Bird H (2007) Antidepressants in child and adolescent depression: Where are the bugs? Acta Psychiatr Scand. 115: 184-195.
42. Nussbaum A, Stroup TS (2008) Paliperidone for schizophrenia. Cochrane Database Syst Rev. CD006369.
43. Papanikolaou PN, Christidi GD, Ionannidis JP (2006) Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 174: 635-641. (Pubitemid 43341873)
44. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C (2009) Weight effects associated with antipsychotics: A comprehensive database analysis. Schizophr Res. 110: 103-110.
45. Rattehalli RD, Jayaram MB, Smith M (2010) Risperedone versus placebo for schizophrenia. Cochrane Database Syst Rev. CD006918.
46. Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J (2012) The US Food and Drug Administration's sentinel initiative: Expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 21: 9-11.
47. Schechtman E (2002) Odds ratio, relative risk, absolute risk reduction, and the use of number needed to treatVwhich of these should we use? Value Health. 5: 431-436.
48. Sharif ZA (2003) Overview of safety and tolerability of atypical antipsychotics used in primary care. Prim Care Companion J Clin Psychiatry. 5: 14-21.
49. Shinfuku M, Uchida H, Tsutsumii C, Suzuki T, Wantanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S (2012) How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective. Pharmacopsychiatry. 45: 133-137.
50. Srivastava S, Ketter TA (2011) Clinical relevance of treatments for acute bipolar disorder: Balancing therapeutic and adverse effects. Clin Ther. 33:B40-48.
51. Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman D, Jacobson HG (2009) Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. J Clin Psychopharmacol. 29: 520-528.
52. Vanelle JM, Douki S (2006) A double-blind randomized comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 21: 523-530. (Pubitemid 44855531)
53. Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, Molina BS, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R (2012) Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 169: 167-177.
54. Walkup JL, and, the Work Group on Quality Issues (2009) Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 48: 961-973.
55. Warner CH, Bobo W, Warner C, Reid S, Rachal J (2006) Antidepressant discontinuation syndrome. Am Fam Physician. 74: 449-456. (Pubitemid 44285164)
56. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: Results from a 2-year, prospective study in antipsychotic-naBve patients. Neuropsychopharmacol. 38: 1738-1746.
57. Zimmerman M, Chelminski I, Posternak MA (2005) Generalizability of antidepressant efficacy trials: Differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 162: 1370-1372. (Pubitemid 40905589)
58. Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of randomized controlled trials. Eur Neuropsychopharmacol. 21: 600-620.